Bloom Science Australia

Bloom Science is a clinical-stage biotechnology company pioneering a novel class of neuroprotective medicines by harnessing the gut-brain axis. The company utilizes its proprietary Iris platform to identify specific microbes and microbial metabolites that modulate key neurotransmitters like GABA and serotonin to treat neurological and inflammatory diseases. Their lead program, BL-001, is being developed for rare, drug-resistant epilepsies such as Dravet syndrome, with additional programs targeting Amyotrophic Lateral Sclerosis (ALS) and mood disorders. By mimicking the neuroprotective effects of the ketogenic diet through targeted live biotherapeutics, Bloom Science aims to provide transformative, low-toxicity treatments for patients with significant unmet needs.